Article Text

Download PDFPDF

Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al
Free
  1. Christian Dejaco1,2,
  2. Johannes WJ Bijlsma3,
  3. Frank Buttgereit4
  1. 1Rheumatology, Medical University of Graz, Graz, Austria
  2. 2Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy
  3. 3Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands
  4. 4Rheumatology and Immunology, Charitè University, Berlin, Germany
  1. Correspondence to Dr Christian Dejaco, Rheumatology, Medical University of Graz, 8036 Graz, Austria; christian.dejaco{at}gmx.net

Statistics from Altmetric.com

The letter from Al Nokhatha et al nicely complements our study whose primary purpose was to investigate how COVID-19 related closure of services influenced decisions of rheumatologists and health professionals in rheumatology regarding the management of patients with inflammatory rheumatic and musculoskeletal diseases (RMD).1 2 In contrast to the study by Al Nokhatha et al, we did not include data on vaccinations, which were at that time still far away.

The authors of this letter correctly point out that vaccination is fundamental to our patients in order to protect them from adverse outcomes of (certain) infections. However, many patients with inflammatory RMD are immunocompromised, and it is well known that in such a clientele, vaccination is challenging regarding both efficacy and safety. Paget et al recently concluded that influenza vaccination should continuously be promoted during COVID-19 pandemic as a central public health measure.3 The reason is that the evidence accrued so far clearly indicates that the management of the coronavirus pandemic can greatly benefit from influenza vaccination, for example, by facilitating differential diagnosis and by avoiding an overload of health services and hospitals associated with influenza infections.3 4 Also, influenza vaccination protects elderly people which are particularly vulnerable to COVID-19. Al Nokhatha et al noted that there are some barriers to receive influenza vaccination that might also be relevant for ongoing vaccination against SARS-CoV-2: peoples’ fear of adverse reactions, perceived good health, personal lack of belief in the vaccine effectiveness, a reported history of side effects, a lack of recommendation from healthcare workers or lack of access to the vaccine.1 The authors of this correspondence have experienced some additional obstacles during COVID-19 pandemic such as patients’ fear to enter health service structures, lack of manpower to adequately organise and conduct vaccination, lack of vaccine and patients’ fear that influenza vaccination might lower the defence against COVID-19.

Given the vulnerability of patients with inflammatory RMD to infections, we need to make sure that our patients undergo influenza and SARS-CoV-2 vaccinations. We should develop strategies to address patients’ specific concerns about the new vaccine, such as the fact that the vaccines have not been specifically tested in patients with autoimmune disease or that possible long-term consequences of SARS-CoV-2 vaccination are unknown yet.

In accordance with a recent statement from 'European League Against Rheumatism,5 we think that rheumatologists should be the primary experts to discuss these issues with their patients. Moreover, national societies of rheumatology should launch public programmes influencing mass opinion in order to convince patients with RMD, their relatives and friends, that vaccination against SARS-CoV-2 is the only way to protect people from COVID-19.

References

Footnotes

  • Handling editor Josef S Smolen

  • Contributors All authors drafted the manuscript together and approved its final version.

  • Funding European League against Rheumatism (EULAR), project number EPI025.

  • Competing interests CD received consulting/speaker’s fees from Abbvie, Eli Lilly, Janssen, Novartis, Pfizer, Roche and Sanofi, as well as grant support from Celgene, all unrelated to this manuscript. JWJB received honoraria from Lilly, Roche, Abbvie, Galapagos, SUN all unrelated to this manuscript. FB received consulting/speaker’s fees from Abbvie, Lilly, Horizon Therapeutics, Pfizer and Roche/Chugai, all unrelated to this manuscript.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles